Financial Times·4h agoLLY
Obesity drug supply constraints ease as new capacity comes online
Two additional fill-finish sites received clearance, shortening lead times in the US and EU markets.
Eli Lilly and Company
$812.35+2.47%
Eli Lilly and Company
LLY$812.35+2.47%
$916.47$874.04$831.62$789.19$746.76
Jul 11Jul 19Jul 26Aug 3Aug 10
About Eli Lilly and Company
Eli Lilly discovers, develops and markets pharmaceutical products across diabetes, obesity, oncology, immunology and neuroscience therapeutic areas.
Market cap$771.8B
P/E74.1
Dividend0.65%
52W high$972.53
52W low$677.09
Revenue$45.0B
EPS10.99
Employees43,000
CEODavid A. Ricks
SectorHealthcareDrug Manufacturers
About Eli Lilly and Company
Eli Lilly discovers, develops and markets pharmaceutical products across diabetes, obesity, oncology, immunology and neuroscience therapeutic areas.
Market cap$771.8B
P/E74.1
Dividend0.65%
52W high$972.53
52W low$677.09
Revenue$45.0B
EPS10.99
Employees43,000
CEODavid A. Ricks
SectorHealthcareDrug Manufacturers
Latest news
Discussion
The interesting part of this print isn't the top line, it's that gross margin held while mix shifted toward the lower-margin segment.